Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhazzani, Khalid, Alsahli, Meshal, Alanazi, Ahmed Z, Algahtani, Mohammad, Alenezi, Ahmad A, Alhoshani, Ali, Alqinyah, Mohammed, Alhamed, Abdullah S., Alhosaini, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495648/
https://www.ncbi.nlm.nih.gov/pubmed/37705877
http://dx.doi.org/10.1016/j.jsps.2023.101756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495648/
https://www.ncbi.nlm.nih.gov/pubmed/37705877
http://dx.doi.org/10.1016/j.jsps.2023.101756

Ejemplares similares